Search

Your search keyword '"Hoffmann, Marc S."' showing total 31 results
Start Over Author "Hoffmann, Marc S."
31 results on '"Hoffmann, Marc S."'

1. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study

Author

Wierda, William G, Shah, Nirav N, Cheah, Chan Y, Lewis, David, Hoffmann, Marc S, Coombs, Catherine C, Lamanna, Nicole, Ma, Shuo, Jagadeesh, Deepa, Munir, Talha, Wang, Yucai, Eyre, Toby A, Rhodes, Joanna M, McKinney, Matthew, Lech-Maranda, Ewa, Tam, Constantine S, Jurczak, Wojciech, Izutsu, Koji, Alencar, Alvaro J, Patel, Manish R, Seymour, John F, Woyach, Jennifer A, Thompson, Philip A, Abada, Paolo B, Ho, Caleb, McNeely, Samuel C, Marella, Narasimha, Nguyen, Bastien, Wang, Chunxiao, Ruppert, Amy S, Nair, Binoj, Liu, Hui, Tsai, Donald E, Roeker, Lindsey E, and Ghia, Paolo

Published
2024
Full Text
View/download PDF

4. Rare presentation and unconventional treatment of Rosai–Dorfman disease.

Author

Proskuriakova, Ekaterina, Shunyakov, Leonid, and Hoffmann, Marc S.

Abstract

Rosai–Dorfman disease (RDD) is a rare myeloproliferative disorder involving histiocytes, with an incidence of 1:200 000 and approximately 100 new cases diagnosed annually in the USA. The condition presents a diverse range of clinical manifestations, and early recognition and treatment generally result in a favourable prognosis. However, diagnosing RDD poses challenges due to its rarity. The clinical management of RDD lacks a consensus, further complicating its diagnostic and therapeutic approach. We present a case of a man in his late 50s with RDD who experienced worsening cytopenias, including severe neutropenia and respiratory distress, despite an initial positive response to steroids, rituximab and lenalidomide. Genetic testing revealed mutations in POLE, KRAS (G13C), NDE1 and EZH2, suggesting potential new therapeutic targets. Sirolimus was initiated and led to complete radiological remission of the disease. This case adds strength to the growing evidence supporting the efficacy of sirolimus in refractory RDD cases. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. P1108: EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: RESULTS FROM THE PHASE 1/2 BRUIN STUDY

Author

Scarfò, Lydia, primary, Patel, Manish R., additional, Eyre, Toby A., additional, Jurczak, Wojciech, additional, Lewis, David, additional, Gastinne, Thomas, additional, MA, Shuo, additional, Cohen, Jonathon B., additional, Patel, Krish, additional, Brown, Jennifer R., additional, Munir, Talha, additional, Lech-Maranda, Ewa, additional, Hoffmann, Marc S., additional, Ujjani, Chaitra S., additional, Fakhri, Bita, additional, Wang, Michael, additional, Izutsu, Koji, additional, Nagai, Hirokazu, additional, Tam, Constantine S., additional, Seymour, John F., additional, Rhodes, Joanna, additional, Vose, Julie, additional, Mckinney, Matthew, additional, Gerson, James N., additional, Barve, Minal A., additional, Kuss, Bryone, additional, Koh, Youngil, additional, Gao, Wei, additional, Ruppert, Amy S., additional, Walgren, Richard A., additional, Tsai, Donald E., additional, Nair, Binoj, additional, Bao, Katherine, additional, Mato, Anthony R., additional, Cheah, Chan Y., additional, and Lia Palomba, M, additional

Published
2023
Full Text
View/download PDF

8. Abstract CT167: Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: Results from the phase 1/2 BRUIN study

Author

Rhodes, Joanna, primary, Lewis, David, additional, Ghia, Paolo, additional, Shah, Nirav N., additional, Coombs, Catherine C., additional, Cheah, Chan Y., additional, Woyach, Jennifer, additional, Lamanna, Nicole, additional, Hoffmann, Marc S., additional, Ma, Shuo, additional, Eyre, Toby A., additional, Munir, Talha, additional, Patel, Manish R., additional, Alencar, Alvaro J., additional, Tam, Constantine S., additional, Seymour, John F., additional, Jurczak, Wojciech, additional, Lech-Maranda, Ewa, additional, Roeker, Lindsey E., additional, Thompson, Philip A., additional, Abada, Paolo B., additional, Wang, Chunxiao, additional, Nair, Binoj, additional, Liu, Hui, additional, Tsai, Donald E., additional, Mato, Anthony R., additional, and Wierda, William G., additional

Published
2023
Full Text
View/download PDF

9. ABCL-503 Golcadomide (GOLCA; CC-99282), a Potential First-in-Class Oral CELMoD™ Agent, With R-CHOP, As First-line (1L) Therapy in Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy in an Open-Label, Multicenter, Phase 1b Trial

Author

Westin, Jason, Hoffmann, Marc S., Vassilakopoulos, Theodoros, Munoz, Javier L., Jurczak, Wojciech, Yeh, Su-Peng, Zimowska-Curyło, Dagmara, Kwiatek, Michał, Martín García-Sancho, Alejandro, Sudhindra, Akshay, Gkasiamis, Argyrios, Patel, Arpankumar, Boucaud, Floriane, Petel, Adrien, Kaplan, Mark, Basavanhally, Tara, Li, Ju, and Nowakowski, Grzegorz

Published
2024
Full Text
View/download PDF

10. Golcadomide (GOLCA; CC-99282), a Potential First-in-Class Oral CELMoD™ Agent, With R-CHOP, As First-Line (1L) Therapy in Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy in an Open-Label, Multicenter, Phase 1b Trial

Author

Westin, Jason, Hoffmann, Marc S., Vassilakopoulos, Theodoros, Munoz, Javier L., Jurczak, Wojciech, Yeh, Su-Peng, Zimowska-Curyło, Dagmara, Kwiatek, Michał, Martín García-Sancho, Alejandro, Sudhindra, Akshay, Gkasiamis, Argyrios, Patel, Arpankumar, Boucaud, Floriane, Petel, Adrien, Kaplan, Mark, Basavanhally, Tara, Li, Ju, and Nowakowski, Grzegorz

Published
2024
Full Text
View/download PDF

14. Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

Author

Cohen, Jonathon B., Shah, Nirav N., Jurczak, Wojciech, Zinzani, Pier Luigi, Cheah, Chan Y., Eyre, Toby A., Ujjani, Chaitra S, Koh, Youngil, Kim, Won Seog, Nasta, Sunita D., Flinn, Ian W., Tessoulin, Benoit, Ma, Shuo, Alencar, Alvaro J., Lewis, David, Woyach, Jennifer A., Maddocks, Kami J., Patel, Krish, Wang, Yucai, Rhodes, Joanna M., Tam, Constantine S., Seymour, John F., Nagai, Hirokazu, Vose, Julie M., Fakhri, Bita, Hoffmann, Marc S., Hernandez-Ilizaliturri, Francisco J., Zelenetz, Andrew D., Kumar, Anita, Munir, Talha, Tsai, Donald E., Balbas, Minna, Liu, Bin, Ruppert, Amy S., Nguyen, Bastien, Roeker, Lindsey E., and Wang, Michael L.

Published
2023
Full Text
View/download PDF

16. Golcadomide (GOLCA; CC-99282), a Novel CELMoD Agent, Plus R-CHOP in Patients (pts) with Previously Untreated Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy Results from Phase 1b Dose Expansion

Author

Hoffmann, Marc S., Munoz, Javier L., Westin, Jason, Vassilakopoulos, Theodoros, Martin Garcia-Sancho, Alejandro, Rueda Dominguez, Antonio, Jurczak, Wojciech, Yeh, Su-Peng, Bouzani, Maria, Gkasiamis, Argyrios, Kaplan, Mark, Patel, Arpankumar, Boucaud, Floriane, Li, Ju, and Nowakowski, Grzegorz S.

Published
2023
Full Text
View/download PDF

20. Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study

Author

Wierda, William G., Shah, Nirav N., Cheah, Chan Yoon, Lewis, David, Hoffmann, Marc S., Coombs, Catherine C., Lamanna, Nicole, Ma, Shuo, Jagadeesh, Deepa, Munir, Talha, Wang, Yucai, Eyre, Toby A., Rhodes, Joanna M., McKinney, Matthew, Lech-Maranda, Ewa, Tam, Constantine S., Jurczak, Wojciech, Izutsu, Koji, Alencar, Alvaro J., Patel, Manish, Seymour, John F., Woyach, Jennifer A., Roeker, Lindsey E., Thompson, Philip A., Abada, Paolo, Ho, Caleb, Marella, Narasimha, Wang, Chunxiao, Ruppert, Amy S., Chandrasekharan Nair, Binoj, Liu, Hui, Tsai, Donald E., and Ghia, Paolo

Published
2023
Full Text
View/download PDF

24. Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study

Author

Patel, Krish, Vose, Julie M., Nasta, Sunita D., Brown, Jennifer R., Maddocks, Kami J., Woyach, Jennifer A., Shah, Nirav N., Fakhri, Bita, Tessoulin, Benoit, Ma, Shuo, Jagadeesh, Deepa, Lech-Maranda, Ewa, Coombs, Catherine C., Patel, Manish, Rhodes, Joanna M., Ujjani, Chaitra S, Hoffmann, Marc S., Cheah, Chan Y, Munir, Talha, Lewis, David, Scarfo, Lydia, Eyre, Toby A., Alencar, Alvaro J., Cohen, Jonathon B., Zelenetz, Andrew D., Tsai, Donald E., Li, Mei, Bian, Faith, Abada, Paolo, and Zinzani, Pier Luigi

Abstract

Background:Marginal zone lymphoma (MZL) is an indolent lymphoma that is typically treated with chemoimmunotherapy, but often requires sequential therapy. Covalent (c) Bruton tyrosine kinase inhibitors (BTKi) are increasingly being used in the relapsed or refractory (R/R) setting, but options for pts with MZL after cBTKi therapy may be limited. Pirtobrutinib, a highly selective, non-covalent (reversible) BTKi has favorable once daily oral pharmacology that enables continuous BTK inhibition throughout the dosing interval, regardless of intrinsic rate of BTK turnover. Pirtobrutinib has demonstrated promising efficacy and tolerability in pts with poor-prognosis B-cell malignancies following prior therapy, including prior cBTKi. Pirtobrutinib is approved in the USA to treat R/R mantle cell lymphoma after at least two lines of systemic therapy including prior BTKi treatment. Here we report the safety and efficacy of pirtobrutinib in pts with MZL from the BRUIN study (NCT03740529).

Published
2023
Full Text
View/download PDF

29. Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.

Author

Shah NN, Wang M, Roeker LE, Patel K, Woyach JA, Wierda WG, Ujjani CS, Eyre TA, Zinzani PL, Alencar AJ, Ghia P, Lamanna N, Hoffmann MS, Patel MR, Flinn I, Gerson JN, Ma S, Coombs CC, Cheah CY, Lech-Maranda E, Fakhri B, Kim WS, Barve MA, Cohen JB, Jurczak W, Munir T, Thompson MC, Tsai DE, Bao K, Cangemi NA, Kherani JF, Walgren RA, Han H, Ruppert AS, and Brown JR

Abstract

Bruton tyrosine kinase inhibitors (BTKi) have transformed the treatment of B-cell malignancies, but intolerance has often led to their discontinuation. The phase 1/2 BRUIN study evaluated pirtobrutinib, a highly selective non-covalent (reversible) BTKi, in patients with R/R B-cell malignancies (NCT03740529). Pirtobrutinib was investigated in 127 patients with intolerance to at least one prior BTKi therapy in the absence of progressive disease. The most common adverse event (AE) leading to BTKi discontinuation was cardiac disorders (n=40, 31.5%), specifically atrial fibrillation (n=30, 23.6%). The median follow-up was 17.4 months and the median time on pirtobrutinib was 15.3 months. The most common reasons for pirtobrutinib discontinuation were progressive disease (26.8%), AE (10.2%), or death (5.5%). The most frequent treatment-emergent AEs were fatigue (39.4%) and neutropenia (37.0%). Among patients who discontinued a prior BTKi for a cardiac issue, 75% had no recurrence of their cardiac AE. No patient discontinued pirtobrutinib for the same AE that led to discontinuation of the prior BTKi. In 78 CLL/SLL and 21 MCL patients intolerant to prior BTKi, ORR to pirtobrutinib was 76.9% and 81.0%, respectively. Median PFS for CLL/SLL was 28.4 months and was not estimable for MCL. These results suggest that pirtobrutinib was safe, well-tolerated, and an efficacious option in patients with prior BTKi-intolerance.

Published
2024
Full Text
View/download PDF

31. Acute benzodiazepine toxicity exacerbated by concomitant oral olanzapine.

Author

Hoffmann MS, Overman MJ, and Nates JL

Abstract

Improvements in antiemetic therapy constitute a major advance in oncology. A recent poll of the oncology community by the American Society of Clinical Oncology ranked it as one of the top 5 advances in cancer in the last 50 years. Emetogenicity of chemotherapy is defined by risk of emesis in the patient given no antiemetics; high-risk regimens cause nausea and vomiting in >90% of patients, moderate risk in 30%-90%, and low risk in <30%. This risk profile serves as the basis for empiric antiemetic prophylaxis and offers alternatives to refractory patients. Modern antiemetic prophylaxis is extremely effective for high-risk chemotherapy, reducing the risk for breakthrough nausea and vomiting to 0%-13% in the acute setting (<24 hours from receipt of chemotherapy) and to 25%-30% in the delayed setting (24-72 hours from receipt of chemotherapy)., (©2016 Frontline Medical Communications.)

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results